Thomas Jensen

Company: Allarity Therapeutics

Job title: Chief Executive Officer

Seminars:

Enhancing Patient Selection in Oncology: Clinical Validation of a Multi- Gene Expression Diagnostic to Predict Sensitivity to DDR Therapies 2:15 pm

Introduction to Allarity’s Drug Response Predictor (DRP)- a multi-gene expression diagnostic for selecting patients likely to benefit from DDR therapies Sharing key findings from the phase II advanced, recurrent ovarian cancer study showcasing the impact of Allarity’s novel PARP/ Tankyrase inhibitor, Stenoparib A discussion of Stenoparib’s potential in advanced ovarian cancer using the Stenoparib DRP…Read more

day: Day Two